Status:
COMPLETED
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension
- Patients who are eligible and able to participate in the study
- Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of Hypertensive encephalopathy or cerebrovascular accident
- Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
1797 Patients enrolled
Trial Details
Trial ID
NCT00219180
Start Date
June 1 2005
End Date
September 1 2006
Last Update
May 17 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany